Ruben Pio

Summary

Affiliation: University of Navarra
Country: Spain

Publications

  1. doi request reprint Prognostic signature of early lung adenocarcinoma based on the expression of ribonucleic acid metabolism-related genes
    Ruben Pio
    Program in Solid Tumors and Biomarkers, Center for Applied Medical Research CIMA, Pamplona, Spain Department of Biochemistry and Genetics, School of Science, University of Navarra, Pamplona, Spain Navarra s Health Research Institute IDISNA, Pamplona, Spain Electronic address
    J Thorac Cardiovasc Surg 150:986-92.e1-11. 2015
  2. pmc The role of complement in tumor growth
    Ruben Pio
    Oncology Division CIMA, and Department of Biochemistry and Genetics School of Science, University of Navarra, Pamplona, Spain
    Adv Exp Med Biol 772:229-62. 2014
  3. doi request reprint Complement factor H is elevated in bronchoalveolar lavage fluid and sputum from patients with lung cancer
    Ruben Pio
    Division of Oncology, Center for Applied Medical Research, Universidad de Navarra, Pamplona, Spain
    Cancer Epidemiol Biomarkers Prev 19:2665-72. 2010
  4. ncbi request reprint Identification, characterization, and physiological actions of factor H as an adrenomedullin binding protein present in human plasma
    Ruben Pio
    Department of Biochemistry and Carcinogenesis Unit, University of Navarra, Pamplona, 31080 Spain
    Microsc Res Tech 57:23-7. 2002
  5. pmc Development of a novel splice array platform and its application in the identification of alternative splice variants in lung cancer
    Ruben Pio
    Division of Oncology, Center for Applied Medical Research, Pamplona, Spain
    BMC Genomics 11:352. 2010
  6. doi request reprint Alternative splicing in lung cancer
    Ruben Pio
    Division of Oncology, Center for Applied Medical Research and School of Medicine, University of Navarra, Pamplona, Spain
    J Thorac Oncol 4:674-8. 2009
  7. ncbi request reprint Alpha CP-4, encoded by a putative tumor suppressor gene at 3p21, but not its alternative splice variant alpha CP-4a, is underexpressed in lung cancer
    Ruben Pio
    Division of Oncology and Department of Biochemistry, Clinica Universitaria and School of Medicine, Center for Applied Medical Research, University of Navarra, Pamplona, Spain
    Cancer Res 64:4171-9. 2004
  8. doi request reprint The oncoprotein SF2/ASF promotes non-small cell lung cancer survival by enhancing survivin expression
    Teresa Ezponda
    Department of Pathology, Clinica Universidad de Navarra, Pamplona, Spain
    Clin Cancer Res 16:4113-25. 2010
  9. pmc Silica-induced chronic inflammation promotes lung carcinogenesis in the context of an immunosuppressive microenvironment
    Javier Freire
    Center for Applied Medical Research CIMA, Pamplona, Spain
    Neoplasia 15:913-24. 2013
  10. ncbi request reprint Altered patterns of expression of members of the heterogeneous nuclear ribonucleoprotein (hnRNP) family in lung cancer
    Irene Pino
    Department of Histology and Pathology, School of Medicine and University Hospital, University of Navarra, 1 Irunlarrea Street, P O Box 177, 31080 Pamplona, Spain
    Lung Cancer 41:131-43. 2003

Detail Information

Publications45

  1. doi request reprint Prognostic signature of early lung adenocarcinoma based on the expression of ribonucleic acid metabolism-related genes
    Ruben Pio
    Program in Solid Tumors and Biomarkers, Center for Applied Medical Research CIMA, Pamplona, Spain Department of Biochemistry and Genetics, School of Science, University of Navarra, Pamplona, Spain Navarra s Health Research Institute IDISNA, Pamplona, Spain Electronic address
    J Thorac Cardiovasc Surg 150:986-92.e1-11. 2015
    ..The objective of this study was to validate a prognostic signature based on the expression of 5 RNA (ribonucleic acid) metabolism-related genes...
  2. pmc The role of complement in tumor growth
    Ruben Pio
    Oncology Division CIMA, and Department of Biochemistry and Genetics School of Science, University of Navarra, Pamplona, Spain
    Adv Exp Med Biol 772:229-62. 2014
    ..This chapter reviews the data describing the role of complement activation in cancer immunity, which offers insights that may aid the development of more effective therapeutic approaches to control cancer. ..
  3. doi request reprint Complement factor H is elevated in bronchoalveolar lavage fluid and sputum from patients with lung cancer
    Ruben Pio
    Division of Oncology, Center for Applied Medical Research, Universidad de Navarra, Pamplona, Spain
    Cancer Epidemiol Biomarkers Prev 19:2665-72. 2010
    ..The use of molecular biomarkers may enhance the sensitivity of cytologic examination in the detection of lung cancer...
  4. ncbi request reprint Identification, characterization, and physiological actions of factor H as an adrenomedullin binding protein present in human plasma
    Ruben Pio
    Department of Biochemistry and Carcinogenesis Unit, University of Navarra, Pamplona, 31080 Spain
    Microsc Res Tech 57:23-7. 2002
    ..The elucidation of the mechanisms that modulate AM activity will be necessary for the understanding of the role of AM in normal and pathological conditions...
  5. pmc Development of a novel splice array platform and its application in the identification of alternative splice variants in lung cancer
    Ruben Pio
    Division of Oncology, Center for Applied Medical Research, Pamplona, Spain
    BMC Genomics 11:352. 2010
    ..In this study, a novel splice array approach was developed, including the design of a high-density oligonucleotide array, a labeling procedure, and an algorithm to identify splice events...
  6. doi request reprint Alternative splicing in lung cancer
    Ruben Pio
    Division of Oncology, Center for Applied Medical Research and School of Medicine, University of Navarra, Pamplona, Spain
    J Thorac Oncol 4:674-8. 2009
    ..The potential significance of alternative splicing as a target for lung cancer diagnosis or treatment will also be discussed...
  7. ncbi request reprint Alpha CP-4, encoded by a putative tumor suppressor gene at 3p21, but not its alternative splice variant alpha CP-4a, is underexpressed in lung cancer
    Ruben Pio
    Division of Oncology and Department of Biochemistry, Clinica Universitaria and School of Medicine, Center for Applied Medical Research, University of Navarra, Pamplona, Spain
    Cancer Res 64:4171-9. 2004
    ..Finally, induction of alpha CP-4 expression reduced cell growth, in agreement with its proposed role as a tumor suppressor, and suggesting an association of this RNA-binding protein with lung carcinogenesis...
  8. doi request reprint The oncoprotein SF2/ASF promotes non-small cell lung cancer survival by enhancing survivin expression
    Teresa Ezponda
    Department of Pathology, Clinica Universidad de Navarra, Pamplona, Spain
    Clin Cancer Res 16:4113-25. 2010
    ..In the present work, we examined the role of SF2/ASF in human non-small cell lung cancer (NSCLC) and analyzed the molecular mechanisms involved in SF2/ASF-related carcinogenesis...
  9. pmc Silica-induced chronic inflammation promotes lung carcinogenesis in the context of an immunosuppressive microenvironment
    Javier Freire
    Center for Applied Medical Research CIMA, Pamplona, Spain
    Neoplasia 15:913-24. 2013
    ....
  10. ncbi request reprint Altered patterns of expression of members of the heterogeneous nuclear ribonucleoprotein (hnRNP) family in lung cancer
    Irene Pino
    Department of Histology and Pathology, School of Medicine and University Hospital, University of Navarra, 1 Irunlarrea Street, P O Box 177, 31080 Pamplona, Spain
    Lung Cancer 41:131-43. 2003
    ..In SCLC cell lines, hnRNP A1 protein expression correlated with that of Bcl-x(L). In the lung cancer cell lines, hnRNP K protein localization varied with the cellular confluence...
  11. doi request reprint Phosphorylated tubulin adaptor protein CRMP-2 as prognostic marker and candidate therapeutic target for NSCLC
    Erik Oliemuller
    Oncology Division, Center for Applied Medical Research CIMA, University of Navarra, 55 Pamplona, Spain
    Int J Cancer 132:1986-95. 2013
    ..These results pointed to CRMP-2 phosphorylation as a prognostic marker and potential new target to be explored in cancer therapy...
  12. pmc Complement activation mediates cetuximab inhibition of non-small cell lung cancer tumor growth in vivo
    Yi Fan Hsu
    Division of Oncology, Center for Applied Medical Research CIMA, Pamplona, Spain
    Mol Cancer 9:139. 2010
    ..In this study, we investigated the role of complement activation in the antitumor mechanism of this therapeutic drug...
  13. ncbi request reprint Expression of alpha CP-4 inhibits cell cycle progression and suppresses tumorigenicity of lung cancer cells
    Zafira Castaño
    Division of Oncology, CIMA, University of Navarra, Pamplona, Spain
    Int J Cancer 122:1512-20. 2008
    ..In conclusion, expression of alpha CP-4 can inhibit proliferation and tumorigenesis of lung cancer cells, both in vivo and in vitro, by delaying the progression of the cell cycle...
  14. pmc Investigation of complement activation product c4d as a diagnostic and prognostic biomarker for lung cancer
    Daniel Ajona
    Affiliations of authors Division of Oncology, Center for Applied Medical Research, Pamplona, Spain DA, MJP, LC, Ja, LMM, RP Department of Histology and Pathology MJP, Ja, LMM and Department of Biochemistry and Genetics RP School of Medicine, University of Navarra, Pamplona, Spain Department of Oncology JLP, Department of Pathology MDL, Department of Thoracic Surgery WT, Department of Pulmonary Medicine JPdT, JJZ Clínica Universidad de Navarra, Pamplona, Spain Thoracic Program, Vanderbilt Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN PPM Department of Medicine, University of Valencia, Valencia, Spain CC Department of Medical Oncology, Hospital General Universitario de Valencia, Valencia, Spain CC Molecular Oncology Laboratory, Fundación para la Investigación del Hospital General Universitario de Valencia, Valencia, Spain EJL
    J Natl Cancer Inst 105:1385-93. 2013
    ..There is a medical need for diagnostic biomarkers in lung cancer. We evaluated the diagnostic performance of complement activation fragments...
  15. pmc Expression of tumor-derived vascular endothelial growth factor and its receptors is associated with outcome in early squamous cell carcinoma of the lung
    Maria J Pajares
    Center for Applied Medical Research CIMA and Clinica Universidad de Navarra CUN, University of Navarra, Pamplona, Spain
    J Clin Oncol 30:1129-36. 2012
    ....
  16. pmc Assessment of epidermal growth factor receptor and K-ras mutation status in cytological stained smears of non-small cell lung cancer patients: correlation with clinical outcomes
    Maria D Lozano
    Department of Pathology, University Clinic of Navarra, University of Navarra, Pamplona, Spain
    Oncologist 16:877-85. 2011
    ..Although mutation status is routinely assessed in biopsies, cytological specimens are frequently the only samples available. We determined EGFR and K-ras mutations in cytological samples...
  17. doi request reprint Identification of alternative splicing events regulated by the oncogenic factor SRSF1 in lung cancer
    Fernando J de Miguel
    Authors Affiliations Division of Oncology, Center for Applied Medical Research CIMA Departments of Histology and Pathology and Biochemistry and Genetics, Schools of Science and Medicine, University of Navarra, Pamplona and CEIT and TECNUN, University of Navarra, San Sebastian, Spain
    Cancer Res 74:1105-15. 2014
    ..In conclusion, using a novel analytical tool, we have identified new splicing events regulated by the oncogenic splicing factor SRSF1 in lung cancer...
  18. pmc Smokers with CT detected emphysema and no airway obstruction have decreased plasma levels of EGF, IL-15, IL-8 and IL-1ra
    Juan P de-Torres
    Pulmonary Department, Clinica Universidad de Navarra, University of Navarra, Pamplona, Spain
    PLoS ONE 8:e60260. 2013
    ..Low-grade inflammation and emphysema have been shown to be associated with an increased risk of lung cancer. However, the systemic inflammatory response in patients with emphysema is still unknown...
  19. pmc Anaphylatoxin C5a creates a favorable microenvironment for lung cancer progression
    Leticia Corrales
    Division of Oncology, Center for Applied Medical Research, University of Navarra, Pamplona 31008, Spain
    J Immunol 189:4674-83. 2012
    ..In conclusion, lung cancer cells have the capacity to generate C5a, a molecule that creates a favorable tumor microenvironment for lung cancer progression...
  20. pmc Identification of novel deregulated RNA metabolism-related genes in non-small cell lung cancer
    Iñaki Valles
    Division of Oncology, Center for Applied Medical Research, Pamplona, Spain
    PLoS ONE 7:e42086. 2012
    ..Taken together, these results support the hypothesis that changes in RNA metabolism are involved in the pathogenesis of lung cancer, and identify new potential targets for the treatment of this disease...
  21. ncbi request reprint Down-regulation of human complement factor H sensitizes non-small cell lung cancer cells to complement attack and reduces in vivo tumor growth
    Daniel Ajona
    Division of Oncology, Center for Applied Medical Research, School of Medicine, University of Navarre, Pamplona 31008, Spain
    J Immunol 178:5991-8. 2007
    ..This may have important consequences in the efficiency of complement-mediated immunotherapies...
  22. doi request reprint Inhibitor of differentiation-1 as a novel prognostic factor in NSCLC patients with adenocarcinoma histology and its potential contribution to therapy resistance
    Mariano Ponz-Sarvise
    Departments of Oncology, Pathology, and Thoracic Surgery, Clínica Universidad de Navarra Division of Oncology, Center for Applied Medical Research CIMA, Pamplona, Spain
    Clin Cancer Res 17:4155-66. 2011
    ..Experiments in cell lines and cells derived from malignant pleural effusions (MPE) were also carried out...
  23. pmc Identification of importin 8 (IPO8) as the most accurate reference gene for the clinicopathological analysis of lung specimens
    Paul A Nguewa
    Division of Oncology, Center for Applied Medical Research CIMA, University of Navarra, Avda, Pio XII, 55, 31008 Pamplona, Spain
    BMC Mol Biol 9:103. 2008
    ..Although classical "housekeeping" genes, such as GAPDH, HPRT1, and beta-actin have been widely used in the past, their accuracy as reference genes for lung tissues has not been proven...
  24. ncbi request reprint Expression of complement factor H by lung cancer cells: effects on the activation of the alternative pathway of complement
    Daniel Ajona
    Division of Oncology, Center for Applied Medical Research, Pamplona, Spain
    Cancer Res 64:6310-8. 2004
    ..In summary, we demonstrate the expression of factor H and FHL-1 by some lung cancer cells and analyze the contribution of these proteins to the protection against complement activation...
  25. ncbi request reprint Molecular profiling of computed tomography screen-detected lung nodules shows multiple malignant features
    Maria J Pajares
    Oncology Division, Center for Applied Medical Research, Clinica Universitaria de Navarra, Pamplona, Spain
    Cancer Epidemiol Biomarkers Prev 15:373-80. 2006
    ....
  26. doi request reprint A large-scale analysis of alternative splicing reveals a key role of QKI in lung cancer
    Fernando J de Miguel
    Program in Solid Tumors and Biomarkers, CIMA, 31008 Pamplona, Spain Department of Biochemistry and Genetics, School of Science, University of Navarra, 31008 Pamplona, Spain
    Mol Oncol 10:1437-1449. 2016
    ..11-5.46, P = 0.026). In conclusion, we identified several splicing variants with functional relevance in lung cancer largely regulated by the splicing factor QKI, a tumor suppressor associated with prognosis in lung cancer...
  27. pmc Elevated levels of the complement activation product C4d in bronchial fluids for the diagnosis of lung cancer
    Daniel Ajona
    Program in Solid Tumors and Biomarkers, Center for Applied Medical Research CIMA, Pamplona, Spain
    PLoS ONE 10:e0119878. 2015
    ..7; 95%CI = 0.56-0.83). In conclusion, C4d is consistently elevated in bronchial fluids from lung cancer patients and may be used to improve the diagnosis of the disease. ..
  28. pmc SPACE: an algorithm to predict and quantify alternatively spliced isoforms using microarrays
    Miguel A Anton
    CEIT and TECNUN, University of Navarra, San Sebastian, Spain
    Genome Biol 9:R46. 2008
    ..The results presented here show its robustness and accuracy for real and simulated data...
  29. ncbi request reprint Alternative splicing: an emerging topic in molecular and clinical oncology
    Maria J Pajares
    Oncology Division, Centre for Applied Medical Research, School of Medicine, University of Navarra, Pamplona, Spain
    Lancet Oncol 8:349-57. 2007
    ..The use of alternative splicing as a potential source for new diagnostic, prognostic, predictive, and therapeutic tools is also discussed...
  30. pmc Contrasting responses of non-small cell lung cancer to antiangiogenic therapies depend on histological subtype
    Marta Larrayoz
    Division of Oncology, Center for Applied Medical Research, Pamplona, Spain
    EMBO Mol Med 6:539-50. 2014
    ..In conclusion, this study evaluates for the first time the effect of antiangiogenic drugs in lung SCC murine models in vivo and sheds light on the contradictory results of antiangiogenic therapies in NSCLC. ..
  31. doi request reprint Multiscale in situ analysis of the role of dyskerin in lung cancer cells
    Ignacio Fernandez-Garcia
    Oncology Division, Center for Applied Medical Research, CIMA, University of Navarra, Avda Pio XII 55, Pamplona 31008, Spain
    Integr Biol (Camb) 5:402-13. 2013
    ....
  32. pmc VEGF₁₂₁b and VEGF₁₆₅b are weakly angiogenic isoforms of VEGF-A
    Raul Catena
    Laboratory of Novel Therapeutic Targets, Division of Oncology, Center for Applied Medical Research CIMA, University of Navarra, Pamplona, Spain
    Mol Cancer 9:320. 2010
    ..In the present work we have produced recombinant VEGF₁₂₁/₁₆₅b proteins in the yeast Pichia pastoris and constructed vectors to overexpress these isoforms and assess their angiogenic potential...
  33. pmc Epigenetic alterations leading to TMPRSS4 promoter hypomethylation and protein overexpression predict poor prognosis in squamous lung cancer patients
    María Villalba
    Department of Histology and Pathology, School of Medicine, University of Navarra, Pamplona, Navarra, Spain
    Oncotarget 7:22752-69. 2016
    ..In conclusion, TMPRSS4 is a novel independent prognostic biomarker regulated by epigenetic changes in SCC and a potential therapeutic target in this tumor type, where targeted therapy is still underdeveloped. ..
  34. pmc Combined clinical and genomic signatures for the prognosis of early stage non-small cell lung cancer based on gene copy number alterations
    Ander Aramburu
    Group of Bioinformatics, CEIT and TECNUN, University of Navarra, San Sebastian, Spain
    BMC Genomics 16:752. 2015
    ..The development of a more refined prognostic methodology for early non-small cell lung cancer (NSCLC) is an unmet clinical need. An accurate prognostic tool might help to select patients at early stages for adjuvant therapies...
  35. doi request reprint New syngeneic inflammatory-related lung cancer metastatic model harboring double KRAS/WWOX alterations
    Anne Marie Bleau
    Division of Oncology, Center for Applied Medical Research CIMA, University of Navarra, Pamplona, Spain
    Int J Cancer 135:2516-27. 2014
    ..Overall, our new syngeneic mouse model provides a most valuable tool to study lung cancer metastasis in balb-c mice background and highlights the importance of WWOX deletion in lung carcinogenesis. ..
  36. pmc Complement inhibition in cancer therapy
    Ruben Pio
    Oncology Division, Center for Applied Medical Research CIMA, Pamplona, Spain
    Semin Immunol 25:54-64. 2013
    ....
  37. pmc TGFBI expression is associated with a better response to chemotherapy in NSCLC
    Marta Irigoyen
    Division of Oncology, Center for Applied Medical Research, Universidad de Navarra, Pio XII 55, Pamplona, 31008, Spain
    Mol Cancer 9:130. 2010
    ..Loss of TGFBI expression has been described in several cancers including lung carcinoma, and it has been suggested to act as a tumor suppressor gene...
  38. doi request reprint Successful Immunotherapy against a Transplantable Mouse Squamous Lung Carcinoma with Anti-PD-1 and Anti-CD137 Monoclonal Antibodies
    Arantza Azpilikueta
    Department of Immunology, Center for Applied Medical Research, Universidad de Navarra
    J Thorac Oncol 11:524-36. 2016
    ..However, robust and reliable experimental models to test immunotherapeutic combinations in squamous lung tumors are still lacking...
  39. pmc Expression of sirtuin 1 and 2 is associated with poor prognosis in non-small cell lung cancer patients
    Ivana Grbesa
    Biomarkers Laboratory, Program of Solid Tumors and Biomarkers, Center for Applied Medical Research CIMA, University of Navarra, 31008 Pamplona, Spain Group for Translational Medicine, Division of Molecular Medicine, Rudjer Boskovic Institute, 10000 Zagreb, Croatia
    PLoS ONE 10:e0124670. 2015
    ..Sirtuin 1 (SIRT1) and sirtuin 2 (SIRT2) are NAD+-dependent protein deacetylases involved in the regulation of key cancer-associated genes. In this study we evaluated the relevance of these deacetylases in lung cancer biology...
  40. pmc TRAP1 regulates proliferation, mitochondrial function, and has prognostic significance in NSCLC
    Jackeline Agorreta
    Authors Affiliations Oncology Division, Center for Applied Medical Research CIMA, University of Navarra, Pamplona 2Department of Molecular and Cellular Biology, Centro Nacional de Biotecnologia, Consejo Superior de Investigaciones Cientificas, Madrid, Spain 3Nuffield Department of Clinical Laboratory Sciences 4Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital 5Department of Medical Oncology, University of Oxford, The Churchill Hospital, Oxford, United Kingdom 6Department of Rheumatology and Immunology, Shandong Provincial Hospital, Shandong University, Jinan, China and 7Department of Experimental Oncology, Fondazione IRCCS Istituto Nazionale Tumori, Milano, Italy
    Mol Cancer Res 12:660-9. 2014
    ..008; multivariate analysis, HR: 2.554; 95% confidence interval, 1.085-6.012; P = 0.03). In conclusion, these results demonstrate that TRAP1 impacts the viability of NSCLC cells, and that its expression is prognostic in NSCLC...
  41. pmc Molecular analysis of a multistep lung cancer model induced by chronic inflammation reveals epigenetic regulation of p16 and activation of the DNA damage response pathway
    David Blanco
    Division of Oncology, Center for Applied Medical Research CIMA, Pamplona, Spain
    Neoplasia 9:840-52. 2007
    ..These data suggest the existence of a specific molecular signature of inflammation-driven lung carcinogenesis that shares some, but not all, of the molecular landmarks of chemically induced lung cancer...
  42. doi request reprint Innate immune mediators in cancer: between defense and resistance
    Pedro Berraondo
    Navarra Institute for Health Research IdiSNA, Pamplona, Spain
    Immunol Rev 274:290-306. 2016
    ....
  43. doi request reprint Strategies to design clinical studies to identify predictive biomarkers in cancer research
    Jose Luis Perez-Gracia
    Department of Oncology, University Clinic of Navarra, Pamplona, Spain Health Research Institute of Navarra IDISNA, Pamplona, Spain Electronic address
    Cancer Treat Rev 53:79-97. 2016
    ....
  44. doi request reprint Pharmacokinetics and antitumor efficacy of paclitaxel-cyclodextrin complexes loaded in mucus-penetrating nanoparticles for oral administration
    Patricia Calleja
    Department of Pharmacy and Pharmaceutical Technology, School of Pharmacy, University of Navarra, Calle de Irunlarrea, 1, 31080, Pamplona, Spain
    Nanomedicine (Lond) 9:2109-21. 2014
    ..The authors report a novel approach for enhancing the oral absorption of paclitaxel (PTX) by encapsulation in poly(anhydride) nanoparticles (NPs) containing cyclodextrins and poly(ethylene glycol)...
  45. doi request reprint Combination of a TLR4 ligand and anaphylatoxin C5a for the induction of antigen-specific cytotoxic T cell responses
    Francesc Rudilla
    Gene Therapy and Hepatology Area and Oncology Area, Center for Applied Medical Research, University of Navarra, 31008 Pamplona, Spain
    Vaccine 30:2848-58. 2012
    ..Our results suggest that fusion proteins containing EDA, the anaphylatoxin C5a and the antigen may serve as a suitable strategy for the development of anti-tumor or anti-viral vaccines...